Acurx Pharmaceuticals, Inc. ACXP PHARMA
Company Overview
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -69.70% |
| 6 Months: | -26.85% |
| 3 Months: | -11.73% |
| 1 Month: | -7.14% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)47.64 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 82.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ACXP Acurx Pharmaceuticals, Inc. PHARMA | 1.43 | -0.59 | $6.15M | 0.00% | - | -128.11% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.18M | 2.27M | 2.03M | 1.62M | 1.72M |
| Operating Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.12M | -2.83M | -2.18M | -2.27M | -2.03M | -1.62M | -1.72M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.18M | -2.27M | -2.03M | -1.62M | -1.72M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.15M | -2.25M | -1.99M | -1.58M | -1.68M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -1.28M | -913.36K | -1.31M | -1.47M | -4.00M | -4.64M | -2.67M | -2.62M | -3.54M | -2.90M | -3.45M | -3.11M | -4.38M | -4.12M | -2.82M | -2.15M | -2.25M | -1.99M | -1.58M | -1.68M |
| Diluted EPS | - | - | -0.21 | -0.21 | -0.57 | -0.46 | -0.26 | -0.26 | -0.32 | -0.25 | -0.28 | -0.24 | -0.28 | -5.21 | -3.45 | -2.15 | -1.89 | -1.23 | - | -0.62 |
| R&D Expense | - | 400.74K | 659.98K | 91.91K | 95.07K | 1.13M | 818.89K | 911.69K | 1.59M | 1.02M | 1.74M | 1.35M | 1.56M | 1.83M | 1.20M | 598.80K | 524.21K | 429.69K | - | 341.47K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 12.09M | 14.58M | 14.12M | 8.09M |
| Operating Income | - | - | -12.09M | -14.58M | -14.12M | -8.09M |
| EBITDA | - | - | -12.09M | -14.58M | -14.12M | -8.09M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | - | -12.09M | -14.58M | -14.10M | -7.97M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | -4.60M | - | -12.09M | -14.58M | -14.10M | -7.97M |
| Diluted EPS | -0.74 | - | -22.40 | -23.00 | -17.45 | -5.32 |
| R&D Expense | 2.20M | 2.03M | 4.75M | 6.04M | 5.40M | 1.83M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | 3.22M | - | 9.38M | 7.71M | 3.86M | 7.69M |
| Current Assets | - | - | 9.38M | 7.71M | 3.86M | 7.69M |
| Cash & Equivalents | - | - | 9.11M | 7.47M | 3.71M | 7.56M |
| Inventory | - | - | - | - | - | - |
| Receivables | - | - | 0 | 129.16K | 51.13K | 48.42K |
| Total Liabilities | 522.43K | - | 2.06M | 3.04M | 3.24M | 2.42M |
| Current Liabilities | 472.56K | - | 2.06M | 3.04M | 3.24M | 2.42M |
| Long Term Debt | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - |
| Total Equity | 2.70M | - | 7.32M | 4.67M | 615.12K | 5.27M |
| Shares Outstanding | - | - | 581.38K | 723.41K | 851.53K | 2.35M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.35M | - | -7.54M | -9.80M | -10.38M | -6.79M |
| Investing Cash Flow | - | - | - | - | - | - |
| Financing Cash Flow | 4.04M | - | 3.70M | 8.16M | 6.62M | 10.64M |
| Capital Expenditure | - | - | - | - | - | - |
| Free Cash Flow | - | - | -7.54M | -9.80M | -10.38M | -6.79M |
| Net Change in Cash | - | - | -3.85M | -1.64M | -3.77M | 3.85M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | -170.3% | - | -165.3% | -312.4% | -2,292.7% | -151.2% |
| ROCE % | - | - | -165.3% | -312.4% | -2,296.0% | -153.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 0.56% | 31.10K | $43.23K |
| 2 | Geode Capital Management, LLC | 0.48% | 26.41K | $36.71K |
| 3 | Vanguard Fiduciary Trust Co | 0.29% | 16.20K | $22.52K |
| 4 | Jane Street Group, LLC | 0.28% | 15.73K | $21.86K |
| 5 | Prospect Financial Services LLC | 0.25% | 13.79K | $19.16K |
| 6 | Morgan Stanley | 0.13% | 7.50K | $10.42K |
| 7 | Tower Research Capital LLC (TRC) | 0.05% | 2.74K | $3.81K |
| 8 | Wells Fargo & Company | 0.04% | 2.30K | $3.20K |
| 9 | Westside Investment Management, Inc. | 0.03% | 1.65K | $2.29K |
| 10 | Lanark Financial Inc | 0.03% | 1.50K | $2.08K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ACXP
Acurx Pharmaceuticals Inc (ACXP) (Q2 2026) Earnings Call Highlights: FDA Signals Potential ...
Company advances toward pivotal Phase 3 trial with conditional FDA guidance, while securing funding to support operations for at least one year.
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operation…
Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult‑to‑treat bacterial infections, today announced that the Japan P…
Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that a poster presentation entitled: Microbiome Restora…
Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss i…
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company") is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. Its lead antibiotic candidate,…
ACXP — Frequently Asked Questions
What is the current share price of Acurx Pharmaceuticals, Inc. (ACXP)?
As of 2026-09-19 21:16 PDT, Acurx Pharmaceuticals, Inc. (ACXP) trades at $1.43 on NasdaqCM. Its 52-week range is $1.35 to $8.10.
What is the market capitalisation of ACXP?
Acurx Pharmaceuticals, Inc. (ACXP) has a market capitalisation of $6.15M on NasdaqCM.
What is the P/E ratio of ACXP?
ACXP trades at a trailing price-to-earnings (P/E) ratio of -0.59. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.81.
What is the return on equity (ROE) of ACXP?
ACXP has a return on equity (ROE) of -128.11%.
Is ACXP a good stock to buy?
This page provides a data-driven analysis of Acurx Pharmaceuticals, Inc. (ACXP), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.